BioMarin seeks full approval for VOXZOGO
BioMarin Pharmaceutical (NASDAQ:BMRN) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for full approval of VOXZOGO (vosoritide) in children with achondroplasia, with an FDA decision target date of February 28, 2027.











